GlassScriptPhysician profile
William Burkes
NPI 1659727360
$2,043.18
in general payments reported to CMS, 2019-2025
18 companies · $596 in 2025
The $596 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $130 · 2021: $103 · 2022: $349 · 2023: $169 · 2024: $697 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,461.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $555.23 | 2024-2025 | Inspire |
| Abbvie INC. | $341.18 | 2022-2023 | Durysta, Xen Glaucoma Treatment System |
| Bausch & Lomb Americas INC. | $240.09 | 2024-2025 | Miebo, Xiidra |
| Alcon Vision LLC | $180.10 | 2021-2024 | Clareon, Centurion, Hydrus Microstent |
| Biotissue Holdings INC. | $146.64 | 2024-2025 | |
| Ivantis, INC | $106.88 | 2020 | |
| Harmony Biosciences LLC | $74.43 | 2022-2024 | |
| Amgen INC. | $60.69 | 2024-2025 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $47.55 | 2024 | Eylea Hd |
| Horizon Therapeutics Plc | $46.76 | 2022 | |
| Jazz Pharmaceuticals INC. | $44.30 | 2020-2021 | |
| Glaukos Corporation | $41.09 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $38.36 | 2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $31.77 | 2025 | Syfovre |
| Ocular Therapeutix, INC. | $25.62 | 2025 | Dextenza |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $23.74 | 2025 | Exparel |
| Harrow Eye, LLC | $21.27 | 2024 | Triesence, Iheezo |
| Genentech USA, INC. | $17.48 | 2025 | Vabysmo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Burkes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.